Adoptive T-cell therapy targeting antigens expressed in glioblastoma has emerged as a potential therapeutic strategy to prevent or delay recurrence and prolong overall survival in this aggressive disease setting. Ephrin receptor A3 (EphA3), which is highly expressed in glioblastoma; in particular, on the tumor vasculature and brain cancer stem cells, is an ideal target for immune-based therapies.
| Authors | Martins, P; D'Souza, RCJ; Skarne, N; Lekieffre, L; Horsefield, S; Ranjankumar, M; Li, X; Le, TT; Smith, F; Smith, C; Burrows, J; Day, BW; Khanna, R |
|---|---|
| Journal | Journal for immunotherapy of cancer |
| Pages | |
| Volume | 12 |
| Date | 7/09/2024 |
| Grant ID | |
| Funding Body | |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1136/jitc-2024-009403 |